Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrow-derived cell therapy for ischaemic heart disease.
about
Bone marrow-derived cell transplantation therapy for myocardial infarction: lessons learned and future questionsStem Cell Therapy for the Heart: Blind Alley or Magic Bullet?Stem cells for the treatment of heart failurePredictors of ventricular remodelling in patients with reperfused acute myocardial infarction and left ventricular dysfunction candidates for bone marrow cell therapy: insights from the BONAMI trial.Additive value of adult bone-marrow-derived cell transplantation to conventional revascularization in chronic ischemic heart disease: a systemic review and meta-analysis.Long-term effects of autologous bone marrow stem cell treatment in acute myocardial infarction: factors that may influence outcomes.Human endothelial stem/progenitor cells, angiogenic factors and vascular repair.Bone Marrow Stem Cell Treatment for Ischemic Heart Disease in Patients with No Option of Revascularization: A Systematic Review and Meta-Analysis.Efficacy and safety of bone marrow cell transplantation for chronic ischemic heart disease: a meta-analysis.Emerging roles for integrated imaging modalities in cardiovascular cell-based therapeutics: a clinical perspective.Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34(+) Bone Marrow Mononuclear Cells.Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up.The effect of rigorous study design in the research of autologous bone marrow-derived mononuclear cell transfer in patients with acute myocardial infarction.Direct autologous bone marrow-derived stem cell transplantation for ischemic heart disease: a meta-analysis.Autologous transplantation of blood-derived stem/progenitor cells for ischaemic heart disease.Advancing stem cell therapy from bench to bedside: lessons from drug therapiesStem-cell angiogenesis and regeneration of the heart: review of a saga of 2 decades.Oxidative stress in mesenchymal stem cell senescence: regulation by coding and non-coding RNAs.Adult Stem Cell Therapy for Cardiac Repair in Patients After Acute Myocardial Infarction Leading to Ischemic Heart Failure: An Overview of Evidence from the Recent Clinical Trials.Mesenchymal stromal cell therapy as treatment for ischemic heart failure: the MSC-HF study.Effects of serum reduction and VEGF supplementation on angiogenic potential of human adipose stromal cells in vitro.Transplantation of Allogeneic Pericytes Improves Myocardial Vascularization and Reduces Interstitial Fibrosis in a Swine Model of Reperfused Acute Myocardial Infarction.Impact of bone marrow mononuclear cells therapy on left ventricular function in patients with ST-elevated myocardial infarction: A meta-analysis.
P2860
Q27026874-F880E4F4-FA05-46F1-A581-61192A7F08F3Q28069300-7C0BD9D3-4496-40F5-B0C3-0ABA3FAEDB79Q28082047-A88AF435-F8B4-4272-8ADC-3AE9ED825C95Q33661061-D7BFE446-D8BF-4956-BB24-DDFCF1C5F4EFQ34043802-DC3E26D3-1085-4814-8D25-4A79680282CFQ34288961-64DA3185-6016-43CA-9049-4196811C467BQ34333348-004D1E35-40BE-408A-8E79-746AA470D8C5Q34804229-6F9A4BE7-C0D8-4B8D-94C5-142F7E123FFEQ35290282-D88753A3-3270-4A04-9F0F-E26B49800ED1Q35944159-0D20D8AA-1988-42A7-A988-E6F5A49576B3Q36848798-6E12AB8C-B087-426D-BA9C-6C7E71A83F37Q37216076-C877D49B-83A9-49A5-BFA1-03A82B1C912DQ37372331-AA356DD9-06F2-45A9-A805-48C797069ED5Q37851149-9EB7E7B3-C347-4B6E-98D3-E0022FCE36D6Q37901551-8CF2401F-30D3-4633-B2DB-517AB1815A84Q38245564-98202C7E-B87E-455C-9400-87609CE80E41Q38467240-35512209-684B-4B79-B402-EFABD83F192DQ38648719-83DF6EFC-EDA6-4783-902D-9729EAD32BD8Q38688425-07D6C011-649B-45FB-B571-72FFBB203456Q42333634-85695732-B1B7-47AD-919C-B09CA7F2BE5BQ45005578-0621AC73-B605-43C3-B464-6FB5F59CFAF0Q49875736-4C24C985-98FF-43A9-B855-6F97B20B911BQ55040403-9DAA7BC7-03E1-48F0-8540-1C806860ED42
P2860
Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrow-derived cell therapy for ischaemic heart disease.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Route of delivery and baseline ...... y for ischaemic heart disease.
@ast
Route of delivery and baseline ...... y for ischaemic heart disease.
@en
type
label
Route of delivery and baseline ...... y for ischaemic heart disease.
@ast
Route of delivery and baseline ...... y for ischaemic heart disease.
@en
prefLabel
Route of delivery and baseline ...... y for ischaemic heart disease.
@ast
Route of delivery and baseline ...... y for ischaemic heart disease.
@en
P2093
P2860
P356
P1476
Route of delivery and baseline ...... y for ischaemic heart disease.
@en
P2093
Christopher J Hyde
Enca Martin-Rendon
Susan J Brunskill
Suzanne M Watt
P2860
P304
P356
10.1093/EURJHF/HFP101
P577
2009-08-04T00:00:00Z